AstraZeneca PLC (AZN)vsGlobus Medical (GMED)
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
GMED
Globus Medical
$90.18
+2.72%
HEALTHCARE · Cap: $11.91B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1899% more annual revenue ($58.74B vs $2.94B). GMED leads profitability with a 18.3% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.54. GMED earns a higher WallStSmart Score of 72/100 (B).
AZN
Buy64
out of 100
Grade: C+
GMED
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$184.74
$29.77 discount
Margin of Safety
+40.9%
Fair Value
$149.32
Current Price
$90.18
$59.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Earnings expanding 437.0% YoY
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 24.4%
Revenue surging 25.7% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : GMED
The strongest argument for GMED centers on EPS Growth, Altman Z-Score, Price/Book. Profitability is solid with margins at 18.3% and operating margin at 24.4%. Revenue growth of 25.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : GMED
The primary concerns for GMED are PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a value stock while GMED is a growth play — different risk/reward profiles.
GMED carries more volatility with a beta of 1.09 — expect wider price swings.
GMED is growing revenue faster at 25.7% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
GMED scores higher overall (72/100 vs 64/100), backed by strong 18.3% margins and 25.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Globus Medical
HEALTHCARE · MEDICAL DEVICES · USA
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?